Shanghai Institute of
Chinese Academy of Sciences
Hangzhou Tigermed Co Ltd
3D Medicines (Beijing)
Technology Co Ltd
Biosciences Co Ltd
Pharmaceutical Co Ltd
Time: July 2020
Capital Raised: Series B worth 1.2 billion yuan
Lead Investor: Warburg Pincus
Co-Investors: CMB International, Legend Capital, funds under China Capital Investment Group, Chaos Investment, Alan AMC, Winfast Investment and Shanghai Science Innovation Commission Venture Fund. Series A investors including BioTrack Capital, Yingke PE, Shanghai Atlas Venture Capital and CSPC and related parties continued to add investment.
Purpose: Accelerate the global R&D and product launch of HaiHe’s multiple new anti-tumor drugs.
Sole financial advisor: CEC Capital
General Coordinator of Corporate Restructuring: Boquan Capital
Time: February 2019
Capital Raised: US$136.6 million
Lead Investor: Huagai Capital
Co-Investors: Yingke PE, CSPC, Hillhouse Capital, investment arm of CAS, Shanghai Atlas Venture Capital, BioTrack Capital, Elite Capital and Daehwa Pharmaceutical
Purpose: Accelerate the clinical and preclinical research and development of the company’s multiple innovative original anti-tumor drugs
Many of our investigational products are independently developed and possess global rights and interests. We are open to potential discussions with overseas pharmaceutical and biotechnology companies on mutually-beneficial cooperation, including overseas rights licensing and joint
Haihe has a rich and balanced pipeline, with many of its products having the potential to be used in combination with other blockbuster drugs. We are willing to explore potential cooperation in drug combinations. The combination of immun0-oncology therapy, targeted drugs, and chemotherapy are all within the scope of discussion.
As the company continues to grow, while conducting independent research and development, we will also introduce more high-quality products to further expand our pipeline and product portfolio.